# SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer

> **NCT00272740** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 93 (—)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT00272740
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 93 (—)
- **Last updated:** 2007-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272740, "SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00272740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*